• Back to miR-29a-3p

• Zheng Z, Cui H, Wang Y, Yao W: Downregulation of RPS15A by miR-29a-3p attenuates cell proliferation in colorectal carcinoma. Biosci Biotechnol Biochem. 2019; 83(11):2057-2064.
• Wang X et al.: miR-29a-3p suppresses cell proliferation and migration by downregulating IGF1R in hepatocellular carcinoma. Oncotarget. 2017; 8(49):86592–86603.
• Yang S et al.: Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011; 25:717–729.
• Kwon JJ, Willy JA, Quirin KA, Wek RC, Korc M, Yin XM, Kota J: Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential. Oncotarget. 2016; 7:71635–71650.
• Tréhoux S et al.: Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochim. Biophys. Acta. 2015; 1853(10Pt A):2392–2403.
• Muluhngwi P et al.: The miR-29 transcriptome in endocrine-sensitive and resistant breast cancer cells. Sci. Rep. 2017; 7:5205.
• Yu PN et al.: Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. Int. J. Cancer. 2014;134:542–551.
• Ahmed F, Shiraishi T, Vessella RL, Kulkarni P: Tumor necrosis factor receptor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a. Oncol Rep. 2013; 30(6):2963-8.
• Barkley LR, Santocanale C: MicroRNA-29a regulates the benzo[a]pyrene dihydrodiol epoxide-induced DNA damage response through Cdc7 kinase in lung cancer cells. Oncogenesis. 2013; 2:e57.
• Muluhngwi P et al.: Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. Cancer Lett. 2017; 388:230-238.
• Xu L et al.: Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia. Exp Hematol Oncol. 2014; 3:17.
• Lu Let al.: MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis. Biomed Pharmacother. 2014; 68(1):13-9.
• Xi Z et al.: Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6. Oncotarget. 2017; 8(15):24949-24963.
• Faltejskova P et al.: Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer. Cancer Biomark. 2012; 12(4):199-204.
• Ma JH, Bu X, Wang JJ, Xie YX: MicroRNA-29-3p Regulates Hepatocellular Carcinoma Progression Through NF-κB Pathway. Clin Lab. 2019; 65(5).
• Zhang L et al.: Reduction of miR-29a-3p induced cardiac ischemia reperfusion injury in mice via targeting Bax. Exp Ther Med. 2019; 18(3):1729-1737.
• Müller M et al.: MicroRNA-29a Is a Candidate Biomarker for Alzheimer's Disease in Cell-Free Cerebrospinal Fluid. Mol Neurobiol. 2016; 53(5):2894-2899.
• Huang YQ, Cai AP, Chen JY, Huang C, Li J, Feng YQ: The Relationship of Plasma miR-29a and Oxidized Low Density Lipoprotein with Atherosclerosis. Cell Physiol Biochem. 2016; 40(6):1521-1528.
• Zhao Y, Yuan Y, Qiu C: Underexpression of CACNA1C Caused by Overexpression of microRNA-29a Underlies the Pathogenesis of Atrial Fibrillation. Med Sci Monit. 2016; 22:2175-81.
• Hsu YC et al.: Protective effects of miR-29a on diabetic glomerular dysfunction by modulation of DKK1/Wnt/β-catenin signaling. Sci Rep. 2016; 6:30575.
• Afum-Adjei Awuah A et al.: Dynamics of T-cell IFN-γ and miR-29a expression during active pulmonary tuberculosis. Int Immunol. 2014; 26(10):579-82.
• Ndzi EN et al.: MicroRNA hsa-miR-29a-3p is a plasma biomarker for the differential diagnosis and monitoring of tuberculosis. Tuberculosis. 2019; 114:69-76.
• Yang YL, Wang FS, Li SC, Tiao MM, Huang YH: MicroRNA-29a Alleviates Bile Duct Ligation Exacerbation of Hepatic Fibrosis in Mice through Epigenetic Control of Methyltransferases. Int J Mol Sci. 2017; 18(1):pii: E192.
• Goldschmidt I, Thum T, Baumann U: Circulating miR-21 and miR-29a as Markers of Disease Severity and Etiology in Cholestatic Pediatric Liver Disea